Roby Zomer is the CEO, Managing Director and Co-Founder of MGC Pharmaceuticals (ASX:MXC), an ASX-listed biotech focused on the development of phytocannabinoid medicines.
Welcome to the eighth episode of The Green Fund's CannaCast! The CannaCast will feature pre-eminent figures within the cannabis space, whether it be entrepreneurs, doctors, chefs, or CEO's of cannabis companies, we will be speaking to the people that have made waves in the cannabis industry.
For this episode, we sat down with Roby Zomer, the Managing Director, CEO and Co-Founder of MGC Pharmaceuticals (ASX:MXC) to discuss MGC's achievements in 2020, and the milestones they expect to hit in 2021.
MGC Pharma is an ASX-listed, Europe-based biopharma company that specializes in the development of phytocannabinoid medicines, and operates on a "Nature to Medicine" strategy, having developed a portfolio of cannabinoid and CBD-based medicines for pharmaceutical use.
In this episode of the CannaCast, we chatted with Roby about the current clinical trials MGC has ongoing, including those for CogniCann and ArtemiC – MGC's novel anti-inflammatory formula designed to treat patients suffering from COVID-19.
Today, MGC Pharma announced that it had completed its Phase II trials for ArtemiC, the results of which are scheduled to be published within a month after they're independently reviewed by an external Clinical Research Organisation in accordance with FDA and GCP guidelines.
This episode was produced by Casey Peternell, the introduction theme music was created by Reni Mathason and the CannaCast image was created by Niccole Lim. You can find the episode on our Spotify as well as on Apple Podcasts.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors